SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to fresh highs, with traders pointing to BRIUMVIs growth and upcoming earnings and subcutaneous-trial data. Buyout talkoften centered on Sanofiand short-squeeze speculation are prominent, but no deal is confirmed and some traders question whether the rally is ahead of the underlying results.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Mixed oncology-trial results are driving attention: traders cite BioNTechs BNT113 setback and modest breast-cancer benefit, while bulls point to other promising pipeline readouts and upcoming updates. Debate also reflects concern over the leadership transition and the time needed to turn the pipeline into commercial products.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos reported licensing of an experimental oral GLP-1/GIP drug from Chinas Hengrui has drawn attention, with traders split between viewing it as a strategic move to address competitive gaps and criticizing the early-stage deal as a costly, uncertain bet. The discussion also reflects broader concern about Lillys competition, Novos management and the stocks prolonged decline, alongside hopes that oral Wegovy momentum and upcoming results could improve sentiment.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilio shares are selling off after Q3 results beat expectations and full-year guidance rose, but Q4 organic-growth guidance of 11%12% signaled a slowdown from Q3s 16% pace. Traders are split between viewing the raised annual outlook and earnings strength as positive and worrying that decelerating messaging growth and softer near-term guidance outweigh the beat.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention for its strength as investors discuss rotating from volatile tech and AI stocks into dividend-paying value funds for perceived stability. Traders praise its resilience and recent gains, while others point to pullbacks and warn that rising Treasury yields can make bonds more competitive with dividend stocks.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

ALM is drawing attention amid a sharp selloff, with traders debating broader weakness across mining and critical-minerals stocks alongside uncertainty about Sangdongs production ramp and near-term revenue. Bullish traders point to tungsten supply constraints and the mines move into production, while skeptics want verified output and operating results before buying into the story.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvanas Q3 report, with record sales and revenue growth but an EPS miss and weaker margins, sparked a sharp rally and renewed short-squeeze speculation; traders are also citing the SECs decision to close its investigation without recommending enforcement. The move has drawn competing views, with bulls focused on growth and squeeze potential while bears question profitability, guidance and valuation.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,075,967,326.643147 in circulation. The last known price of Algorand is 0.09515711 USD and is down -0.23 over the last 24 hours. It is currently trading on 586 active market(s) with $49,581,617.87 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid debate over whether its depressed price and rebounds signal a durable bottom or an altcoin-cycle recovery. Bulls point to accumulation potential and Algorands quantum-resistant and tokenization use cases, while bears emphasize its steep long-term losses and repeated failed rallies.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is drawing attention ahead of its quarterly report, with shares near a 52-week high and heavy options activity. Traders are debating whether put buying reflects hedging or bearish bets, while recent positive Phase 3 lung-cancer results for IMDELLTRA with Imfinzi add to optimism about the pipeline.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention ahead of its quarterly results, with traders focused on whether the distribution will be maintained or cut and how CVR Energys performance and IEPs hedging losses affect its finances. The sharp selloff has fueled anxiety about the payout and the companys outlook, while some holders point to IEPs CVR stake and high short interest as reasons for optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives

Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.read more...

CMND Stock Set For Biggest Intraday Gains In Over Three Years  — Here’s Why Retail Is Eyeing Further Upside

Equity

Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.

Silo Pharma Rallies After Securing Key Patent Allowance

Silo Pharma shares are trading higher Tuesday after the EPO signaled intent to grant a patent for its serotonin 4 receptor stress application.read more...

Why Did SILO Stock Soar 85% Today? 

The European Patent Office granted a patent for the company’s novel 5-HT4 Post-Traumatic Stress Disorder (PTSD) prevention therapy.


Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket

SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.read more...

Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline UnitedHealth, Silo Pharma, Phillips 66 In Focus

U.S. stocks rose on Tuesday, following Monday's advances.read more...

Levi Strauss, Greenbrier And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures down, investors should watch Levi Strauss, Silo Pharma, Greenbrier, Mach Natural Resources, and Phoenix Education Partners.read more...

Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know

Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.read more...

Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment

The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.

After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

This account has been verified as an official SILO representative.

Verified Account

Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

SILO Pharma Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Trump also allocated $50 million in federal funding for related research.</li><li>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines.</li><li>Meanwhile, investors are also tracking Silo Pharma, which is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder.</li></ul>Shares of Clearmind Medicines (CMND) surged nearly 65% in pre-market trading on Monday, putting the stock on track for its biggest intraday gain since August 2022, after U.S. President Donald Trump signed an executive order to accelerate access to psychedelic-based treatments.Separately, Clearmind Medicine, on Monday, said its drug CMND-100 met the main goal in an early-stage trial for Alcohol Use Disorder. The treatment showed strong safety, with no serious side effects reported, even at higher doses.<h2 class="st-heading-2">$50M PTSD Boost</h2>On Saturday, Trump signed an executive order to accelerate research and access to psychedelic-based therapies, bringing renewed attention to treatments for post-traumatic stress disorder (PTSD). The order directs the U.S. Food and Drug Administration to fast-track the review of drugs such as Ibogaine, while allocating $50 million in federal funding for related research.Ibogaine, derived from a Central and West African shrub, remains a Schedule I substance in the U.S., though interest is rising among veteran groups exploring its therapeutic potential. Officials say the move could pave the way for reclassification if clinical trials prove successful, with decisions potentially coming as early as this summer.<h2 class="st-heading-2">All Eyes On Clearmind’s Ibogaine Combination Therapy</h2>Clearmind has a patent for a treatment that combines Ibogaine with N-Acylethanolamines, a type of fatty acid amide. The patent builds on Clearmind’s collaboration with SciSparc, in which both companies are developing combination therapies pairing psychedelic compounds with molecules such as Palmitoylethanolamide to improve treatment outcomes.Ibogaine has shown promise in clinical studies for treating opioid, cocaine, and other substance use disorders, making it a potential anti-addiction therapy.<a href="https://stocktwits.com/symbol/SILO">SILO stock</a> was down 3% at the time of writing.<h2 class="st-heading-2">Silo’s SPC-15 Development Gets A Boost</h2>Meanwhile, Silo Pharma (SILO) also generated a strong buzz after Trump’s order. The firm is currently developing SPC-15, a nasal spray designed to help prevent post-traumatic stress disorder. The treatment uses a fast nose-to-brain delivery approach. It is being developed under a faster regulatory pathway, the firm added.“Momentum at the national level around psychedelic therapeutics reflects what the science has been signaling for years—there is a critical need for new approaches to treating mental health conditions. We believe Silo is well positioned with SPC-15 and its broader CNS pipeline to potentially benefit from a more favorable regulatory and clinical environment,” said Eric Weisblum, CEO of Silo Pharma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CMND">CMND</a> on Stocktwits turned ‘extremely bullish, while sentiment for SILO was ‘bullish.’ Message volumes for CMND were ‘extremely high,’ a whopping 535% increase over the past 24 hours, according to Stocktwits data.One user tracking CMND saw the $1.35-$1.37 level as key resistance.<stembedurl>https://stocktwits.com/minimalistreview/message/650748815</stembedurl>Another user highlighted CMND’s “good results,” adding that the stock could climb over $2.<stembedurl>https://stocktwits.com/Maik237/message/650748439</stembedurl>Year-to-date, CMND shares have declined by more than 66%, while SILO stock has climbed by around 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump speaks during a news conference in James S. Brady Press Briefing Room of the White House on April 06, 2026 in Washington, DC. (Photo by Alex Wong/Getty Images)

Clearmind Medicine Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.23
Prev Close	$1.25
Open	$1.24
Dividend Yield	0.00%
50-Day Moving Average	$1.76
Beta	0.95
Avg. Volume	53,671.09
PE Ratio	-0.23

52-Week High	$10.43
52-Week Low	$1.10
Market Capitalization	$1.95M
EPS (Annual)	-$7.57
Price to Book	0.28
Revenue Per Employee	$24,034.00

Feed

News

Sentiment

Fundamentals

Info

SILO Fundamentals